Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences

Simple item page
dc.contributor.authorSaffari, Fatemehen_US
dc.contributor.authorJafarzadeh, Abdollahen_US
dc.date.accessioned2023-08-19T04:52:09Z
dc.date.available2023-08-19T04:52:09Z
dc.date.issued2022-04
dc.description.abstractThe utilization of the monoclonal antibodies (mAbs) as therapeutic agents is one of the most favourable fields in immunotherapy. The immunogenicity of mAbs is one of the major parameters that may restrict their therapeutic and diagnostic applications. Rituximab, a chimeric mAb against CD20, is attached to the B-cell membrane-linked CD20 and is used to treat some B-cell-related malignancies, a number of autoantibody-mediated autoimmune disorders and improvement of graft survival. The risk of anti-rituximab antibody (ARA) development and ARA-related adverse events are low in rituximab-treated patients with lymphoma. No important association was reported between the ARA positivity and drug levels, and drug efficacy in rituximab-treated patients with lymphoma. The patients with autoimmune disorders exhibit greater risk of ARA development and ARA-related adverse events. In autoimmune diseases, ARA positivity may have no significant impact on either the drug level or its efficacy, (i.e.), it may reduce drug levels without influencing drug efficacy and, vice versa, or may reduce both drug level as well as its efficacy. The characterization of the parameters affecting the production of ARA can be used to design strategies to reduce the immunogenicity of mAb and promote its efficacy in humans. In this review, the host and therapeutic programme-related parameters affecting the development of the ARA have been discussed to suggest novel insights to reduce ARA-associated adverse events and enhance the drug efficacy.en_US
dc.identifier.affiliationsDepartment of Immunology, Medical School, Kerman University of Medical Sciences, Kerman &en_US
dc.identifier.affiliationsMolecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iranen_US
dc.identifier.citationSaffari Fatemeh, Jafarzadeh Abdollah. Development of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequences. Indian Journal of Medical Research. 2022 Apr; 155(3-4): 335–346en_US
dc.identifier.issn0971-5916
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/223602
dc.languageenen_US
dc.publisherWolters Kluwer – Medknowen_US
dc.relation.issuenumber3-4en_US
dc.relation.volume155en_US
dc.source.urihttps://doi.org/10.4103/ijmr.IJMR_312_19en_US
dc.subjectAnti-rituximab antibodyen_US
dc.subjectimmunogenicityen_US
dc.subjectimmunotherapyen_US
dc.subjectrituximaben_US
dc.titleDevelopment of anti-rituximab antibodies in rituximab-treated patients: Related parameters & consequencesen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
IJMR2022v155n3-4p335.pdf
Size:
748.45 KB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Medical Research